# Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Source: https://onco.cc/trials/nct03260023/  
OnCo record `nct03260023` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Avelumab in penile cancer, run by Transgene, active and no longer recruiting.

## Summary

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers is a phase 1/2 interventional study registered as NCT03260023 by Transgene, with 143 participants enrolled, started 2017-09-01 and due to reach its primary completion in 2024-09-18. Interventions recorded: TG4001, Avelumab. Conditions listed: HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03260023
- Phase: 1/2
- Setting: A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.
- Sponsor: Transgene
- Enrolled: 143

## Sources

- ClinicalTrials.gov NCT03260023: https://clinicaltrials.gov/study/NCT03260023

## Connected records

- cancers: [Penile cancer](https://onco.cc/cancers/penile/)
- drugs: [Avelumab](https://onco.cc/drugs/avelumab/)
- companies: [Transgene](https://onco.cc/companies/transgene/)

---
JSON: https://onco.cc/api/v1/entities/nct03260023.json